type toxins that, in addition to lethal factor and edema factor, include protective antigen (PA), the component necessary for binding and uptake by host cells. Lethal factor is a zinc endopeptidase that cleaves mitogenactivated protein kinase kinases, and edema factor is a potent calmodulin-dependent adenyl cyclase.
Despite the importance of LeTx and ETx during anthrax infection, there has been limited characterization of their cardiovascular effects [6] [7] [8] [9] . Most studies are in small animals, in which measurement of cardiac preload, afterload, and output are difficult and monitoring is of limited duration. The effect of cardiovascular changes with toxin on noncardiac organ dysfunction has also not been assessed. Incomplete understanding of the pathophysiologic effects of LeTx and ETx hampers the development of beneficial supportive strategies. Therefore, in the present investigation recombinant LeTx, ETx, or control challenge was infused over 24 h in sedated and instrumented canines receiving mechanical ventilation; canines are an anthrax-susceptible species [10] . Cardiopulmonary, renal, and hepatic mea- a For ETx and LeTx, the dose shows the amount of edema factor (EF) or lethal factor (LF) used. In experiments 1-11, the dose of ETx and LeTx studied was determined on the basis of the survival results from the preceding experiment (see Methods). In experiments 14-20, a fixed dose of LeTx and ETx was studied alone or in combination (8.4 mg/kg LF and EF each). The dose of PA investigated in an experiment was equal to double the dose of EF or LF studied. Experiments 12 and 13 tested the effect of the dose of PA that would be used when fixed doses of LeTx and ETx were investigated.
surements were performed up to 72 h after completion of toxin infusions. To define the influence of fluid administration on the hemodynamic effects of the toxins, measurements were repeated daily after volume loading. An initial study (study 1) investigated and compared the individual effects of similarly lethal dose ranges of each toxin, and 50% lethal doses (LD 50 ) were determined. A second study (study 2) investigated the effects of an LD 50 of LeTx and an equimolar dose of ETx administered alone and together. Weekly, 1-3 anesthetized purpose-bred beagles had venous, pulmonary and systemic arterial, and urinary catheters and tracheostomy placed as described elsewhere [12] . Anesthesia was weaned, and sedation, maintenance fluid, and mechanical ventilation were initiated and continued using standardized intensive care unit protocols. Maintenance fluid and ventilatory support were maintained at constant levels and were similar in all groups. Cardiopulmonary, renal, hepatic, and complete blood count measurements were obtained immediately before and at 8, 24, 48, 72 , and 96 h after initiation of a 24-h toxin or control (diluent [phosphate-buffered saline] or PA alone) infusion. Some measurements were also obtained serially at 8-h intervals. Once daily after initial measurements, animals received normal saline volume loading (40 mL/kg intravenously over 40 min), and cardiopulmonary measures were repeated. Ejection fraction was determined using ultrasonography. Surviving animals were euthanized after final measures.
METHODS

Study design.
Toxin. Recombinant toxin components were prepared as described elsewhere [13] [14] [15] . Toxin doses are reported as the amount of edema factor or lethal factor used. All animals received similar volumes of toxin or control agent. Control PA doses were equal to doses administered with a toxin factor in the same experiment (Table 1) . In some animals from study 1, serum PA was measured (by enzyme-linked immunosorbent assay), in addition to other parameters.
Statistical methods. In study 1, initial toxin doses used for the up-down design were based on those used in prior rat studies [11, [16] [17] [18] . Doses in subsequent experiments were either increased or decreased by 20% on the basis of the survival results from the preceding experiment. The final LD 50 was determined after survival was reversed in 2 successive experiments. Survival times (study 1) and survival curves (study 2) were analyzed with rank and Wilcoxon tests, respectively.
Serial changes from baseline were analyzed for all parameters using repeated-measures analysis of variance with PROC MIXED in SAS software (version 9.1; SAS Institute). However, for clarity in figures serial toxin effects (ie, toxin minus control) at each time point are shown. Fluid effects represent changes from before to after fluid. It was determined a priori that if changes in controls across the 2 studies were similar they would be combined for analysis, and this was the case. Three animals receiving an estimated LD 50 of LeTx in study 1 were combined with animals receiving LeTx alone ( ) in analysis in study n p 5 2. Differences with were considered to be statistically P р .05 significant, and P values were unadjusted for multiple comparisons. All animals from each group that were alive at a particular time point were included in analysis ( Figure 1C-1E ).
RESULTS
Study 1: Effects of Similarly Lethal Dose Ranges of ETx and LeTx
Survival. Fewer dose adjustments were required to establish LD 50 values with ETx (205 mg/kg) than with LeTx (8.4 mg/kg) ( Table 1 and Figure 1A and 1B). For subsequent analyses of study 1, doses of each toxin associated with no survivors were combined in groups termed "high dose," and doses associated with both survivors and nonsurvivors were combined in groups termed "low dose." Overall, the median time to death in nonsurvivors receiving ETx was shorter than that in nonsurvivors receiving LeTx ( ). With low-dose LeTx, P р .05 MAP decreases lessened late, whereas the effect of both doses on HR progressively increased ( for the time interac-P р .03 tions). After an initial small increase in LVEF, both LeTx doses caused decreases in LVEF ( ) that progressed ( P р .01 P р .02 for the time interactions). Low-dose LeTx increased CI and reduced SVRI ( ), and changes in the latter progressed P р .02 ( for the time interaction). Neither dose of LeTx altered P p .03 PAOP or SVI significantly.
In a comparison of either the low or high doses of the 2 toxins, during infusion (4-24 h) both ETx doses produced greater increases in HR and decreases in CVP than did LeTx ( ) ( Figure 2 ). Both ETx doses also produced greater P р .02 increases in CI and decreases in SVRI than did LeTx, but these differences were statistically significant only with the high doses ( ). After toxin infusion (32-96 h), low and high ETx P р .02 doses produced greater reductions in SVRI than did low and high LeTx doses ( and , respectively). P p .06 P p .03 Renal and hepatic measures. Compared with controls, both low-and high-dose ETx caused increases in blood urea nitrogen (BUN) level ( ) that resolved with the former P ! .0001 but progressed with the latter ( for the time interac-P ! .0001 tions) (Figure 3 ). High-dose ETx caused increases in creatinine (Cr) level ( ) that progressed ( for a time in-P р .001 P p .001 teraction). Both doses increased the BUN:Cr ratio ( ), P ! .0003 Figure 1 . A and B, Survival times associated with decreasing doses of edema (ETx) or lethal (LeTx) toxin in individual animals from study 1 (reported as the dose of edema or lethal factor used). Gray circles indicate doses that were associated with both survivors (survival time, 96 h) and nonsurvivors (survival time, !96 h), and black circles indicate doses for which no animal survived (termed low-and high-dose groups, respectively). C and D, Proportion of animals surviving over time with the administration of either low or high doses of ETx or LeTx or diluent only (controls) in study 1. E, Proportion of animals surviving over time in study 2, which compared LeTx and ETx alone or together with controls. Control animals (C, D, and E ) represent animals investigated in both studies 1 and 2. The horizontal arrow ( †) indicates the 24-h period over which toxin or control challenge was infused. ). Increases or decreases with toxin, compared with controls, are indicated by symbols above or below the dashed horizontal no-effect line, respectively. Because measurements were performed in all animals available for study at each time point, the number of measures used for analysis are shown by the number of animals surviving from each group at a particular time point in the Kaplan-Meier curves in Figure 1C and 1D. For clarity of presentation, however, the toxin effects (ie, toxin minus control) are shown. although the effect of low-dose ETx decreased late (P p for a time interaction 
Compared with controls, both ETx doses reduced circulating neutrophil counts significantly ( ) and platelet counts P p .003 ( and for low and high doses, respectively; data P p .06 P p .05 not shown). High-dose ETx also reduced lymphocyte counts late ( for the time interaction). Neither ETx dose altered P p .05 hemoglobin levels significantly. LeTx did not alter these parameters significantly.
Protective antigen measures. PA levels in phosphate-buffered saline controls ( ) were undetectable. In toxin-chaln p 2 lenged animals, PA levels increased, were at a maximum at 24 h, and subsequently decreased (data not shown). Mean levels ‫ע(‬ standard error of the mean) at 24 h were ng/mL 534 ‫ע‬ 47 ( ) and ng/mL ( ) in the low-and highn p 3 1177 ‫ע‬ 101 n p 2 dose ETx groups, respectively, and ng/mL ( ) and 34 ‫ע‬ 3 n p 6 ng/mL ( ) in the low-and high-dose LeTx groups, 65 ‫ע‬ 11 n p 7 respectively.
Effects of fluid administration on cardiovascular measures. In controls, daily fluid challenges produced consistent increases in CVP, PAOP, MAP, and HR ( for the comparison of P р .01 means of the prefluid measurements with means of the postfluid measurements, averaged over the daily infusions) but not in CI or other hemodynamic parameters (Figure 4) . In patterns that did not differ significantly from those in controls, fluids with both doses of ETx and LeTx increased CVP, PAOP, and MAP. However, contrary to the findings in controls, fluids with both doses of ETx and LeTx increased CI throughout (P р for the comparison of the effects of fluid with toxin with .05 those of fluid with controls) or in patterns that varied with time ( for the time interactions). Similar to controls, P р .02 fluids increased HR with low-dose ETx but decreased it with high-dose ETx ( ). Also different from controls, fluids P р .03 increased SVI with high-dose ETx or LeTx ( ) and in-P р .02 creased LVEF over time with high-dose LeTx ( for the P p .01 time interaction). Fluids did not alter any pulmonary parameter significantly differently in a comparison of control and toxin animals (data not shown).
Study 2: Effects of an LD 50 of LeTx and a Similar Molar Dose of ETx Alone or Together
Survival. Compared with controls (9 of 9 survived), the LD 50 of LeTx caused significant mortality (3 of 8 survived; P p ), whereas the eqimolar dose of ETx did not (4 of 4 survived) .01 ( Figure 1E) 
Postmortem Examination
At postmortem, each animal had thoracic and abdominal cavity fluid volumes quantified. Compared with controls, fluid volume from either cavity did not differ significantly with toxins.
DISCUSSION
The present study is, to our knowledge, the first to use invasive hemodynamic monitoring and cardiac imaging in large animals to examine serial cardiopulmonary, renal, and hepatic effects of anthrax ETx and LeTx alone and together. Although ETx was less lethal than LeTx on a molar basis, similar to rat studies it produced deaths more rapidly [16, 19] . Notably, lethality with toxins occurred up to 54 h after completion of the infusions.
Consistent with its effect on mortality, ETx produced early decreases in MAP, CVP, and SVRI and increases in HR and CI. It also caused striking elevations in the BUN:Cr ratio, consistent with underperfusion of the renal vasculature. However, ETx did not increase hemoglobin or pleural or peritoneal fluid levels and did not worsen respiratory function. Thus, excessive extravasation of fluid did not appear to be a major contributor to the effects of ETx. Nonetheless, despite rapidly evolving hypotension ETx caused early increases in urine output and decreases in serum sodium levels. Therefore, shock with ETx in this canine model may relate to excessive arterial and venous dilation in addition to impaired renal handling of sodium or water.
Because both arteries and veins express anthrax toxin receptors and because edema factor has potent adenyl cyclase activity, ETx may have caused shock in this model via cAMP- mediated vasodilation [20] [21] [22] . Intracellular cAMP lowers cytosolic calcium and myosin phosphorylation in vascular smooth muscle and causes dilation [23, 24] . Increases in cAMP in myocardial pacemaker cells may have also contributed to tachycardia and increased CI with ETx [25, 26] . Finally, as with cholera toxin increased urine output and reduced serum sodium levels with ETx may have been attributable to increases in renal tubular cell cAMP [27] [28] [29] . However, it is possible that ETx-induced adrenal injury may have also contributed to these changes [30] . Increases in AST and ALT levels might reflect either poor perfusion or direct hepatic effects of ETx [20, [30] [31] [32] . Although ETx and LeTx were studied over similarly lethal dose ranges in study 1, LeTx produced smaller or more gradual decreases in MAP, SVRI, and CVP and increases in HR and CI. Notably, both LeTx doses caused progressive reductions in LVEF. These LVEF changes are consistent with those in rodent studies, although their time course was delayed in canines [7] [8] [9] . Thus, although peripheral vascular effects may have contributed to LeTx-induced hemodynamic changes in the canine, myocardial dysfunction may have as well. Although inadequate preload (as reflected by PAOP) did not appear to underlie decreases in LVEF, CVP was reduced and fluid loading increased LVEF with high-dose LeTx. CI did not decrease with changes in LVEF, possibly because HR gradually increased.
Disruption of MAPKKs by lethal factor produces several maladaptive responses, including activation of apoptotic and pyroptotic pathways [33, 34] . The time course of such responses is consistent with changes in organ function noted in this model. LeTx-treated vascular endothelial cells underwent mitogen-activated protein kinase cleavage within 5 h, but subsequent apoptosis occurred over 3 days [35] . LeTx-treated endothelial monolayers demonstrated barrier dysfunction after 2-3 days [36] . Thus, LeTx could cause direct vascular endothelial injury manifesting over several days. Although extravasation of fluid did not appear to be pronounced with LeTx, endothelial injury could also disrupt regulation of vascular tone and myocardial function. Intact MAPKKs contribute to normal smooth muscle contraction [37] . With regard to reductions noted in LVEF, electron microscopy has shown early myocardial changes in mice receiving an LeTx bolus [7] . Also, inhibition of MAPK ERK1/2 produces stress-induced apoptosis and heart failure, whereas augmentation is protective [38] [39] [40] . Although hemodynamic dysfunction may have contributed to organ injury with LeTx, limited changes in the BUN:Cr ratio raises the possibility that renal and possibly liver dysfunction were related in part to direct cellular injury by toxin. In rats, although norepinephrine infusions decreased hypotension with LeTx challenge, a range of doses did not alter survival [41] .
Consistent with findings in rats, lethal LeTx and ETx produced limited pulmonary changes in canines [16, 31] . Furthermore, postmortem exam did not demonstrate excessive pleural fluid. Thus, the pleural effusions and respiratory distress noted in patients with inhalational anthrax may relate to the site of toxin delivery or other factors. For example, purified anthrax cell wall produced substantial inflammatory lung injury in rats [42] .
In this canine model, an LD 50 of LeTx together with a nonlethal but equimolar ETx dose appeared to synergistically worsen survival, compared with LeTx alone. In rats, LeTx and ETx together also decreased survival more than was predicted on the basis of their individual effects, although the difference was not statistically significant [16] . Thus, even if smaller amounts of ETx are produced during infection than LeTx, it may still contribute to mortality [43] . Therefore, toxin-directed therapies for anthrax should likely target both toxins.
In rats, continuous 24-h fluid infusions with LeTx did not increase MBP and decreased survival and oxygenation. With LeTx in canines, however, daily 40-min infusions increased CVP, MBP, and CI and did not alter oxygenation. These differences in rat and canine models may relate to the regimen of fluid administration or to the absence or presence of ventilatory support. Understanding the effects of titrated hemodynamic support on shock during anthrax toxemia will be important.
Measurements of PA in patients with anthrax are not available. However, in cynomologous monkeys challenged with anthrax spores, mean PA levels ‫ע(‬ standard error 200 ϫ LD 50 of the mean) increased from ng/mL at 30 h to 1.3 ‫ע‬ 2.3 ng/mL at 72 h (T.S.M. and G.M.S., unpublished 178.3 ‫ע‬ 37.4 data). Thus, although peak PA levels in canines challenged with ETx were almost a log higher than in those with spore challenge, levels with LeTx were more similar.
The present findings are relevant considering the recent softtissue anthrax infections in the United Kingdom [44] . Notably, after initial debridement, antibiotics, and 3-5 days of relative stability some nonsurvivors developed shock refractory to fluid resuscitation and vasopressors. These events may represent recurrent local infection with bacteremia and septic shock. However, results in this canine study raise 2 other possibilities. First, early recurrence of local infection with increasing intravascular release of toxin-most importantly ETx, with its potential to rapidly increase intracellular cAMP levels-could cause vasodilation and inhibition of vasopressors [37, 45, 46] . In this case, agents countering increased intracellular cAMP levels or their downstream effects might be considered. Second, LeTx produced early during infection may lead to progressive cellular dysfunction. Such changes might not be reversible with conventional hemodynamic support. As cited, although norepinephrine ameliorated shock with LeTx in rats, it did not improve survival. Therapy for this second possibility would require understanding the intracellular pathways disrupted by LeTx that have late, life-threatening manifestations.
In conclusion, the present study further delineates the differing effects that anthrax ETx and LeTx have on cardiovascular and organ dysfunction, as well as their potential synergistic effects on mortality. Developing optimal therapies to manage toxemia appears to be integral to improving the care of patients with anthrax.
